Gentulizumab

Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].

Product Specifications

Product Name Alternative

Gensci-059

UNSPSC

12352203

Target

CD47

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

97.02

Smiles

[Gentulizumab]

Molecular Weight

(145.97 kDa)

References & Citations

[1]Wang T, et al. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. J Transl Med. 2024 Mar 1;22 (1) :220.